Related Experiment Video
Updated: Feb 16, 2026
A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
The role of dalbavancin in skin and soft tissue infections
Matteo Bassetti1,2, Maddalena Peghin1, Alessia Carnelutti1
1Infectious Disease Division, Azienda Sanitaria Universitaria Integrata, Presidio Ospedaliero Universitario Santa Maria della Misericordia.
Purpose Of Review:
The increase of skin and soft tissue infections (SSTIs) represents a major concern both in community and in the hospital setting. Staphylococcus aureus is the most frequently isolated pathogen, and the rise in infections due to methicillin-resistant Staphylococcus aureus (MRSA) has been associated with inadequate antibiotic treatment and increased morbidity.
Recent Findings:
A number of new antimicrobials with activity against drug-resistant Gram-positive pathogens, including MRSA, have been recently approved for the treatment of SSTIs. New lipoglycopeptides, in particular dalbavancin, are long-acting antibiotics with potential for infrequent administration, offering the possibility for outpatient treatment and early hospital discharge.
Summary:
Dalbavancin is a new lipoglycopeptide showing high activity against Gram-positive bacteria, including drug-resistant strains. Dalbavancin presents a distinctive pharmacokinetic profile with a terminal prolonged half-life of approximately 14 days. This characteristic allows once-weekly dosing interval, avoiding the need for daily dosing and offering an advantage over other compounds for potential use in the outpatient setting or to promote early hospital discharge. Dalbavancin has a favorable adverse effect profile and appears to be a promising new alternative for treatment of SSTIs. We have reviewed the pharmacokinetic properties of dalbavancin and the clinical evidence for its use in complicated SSTIs and other potential applications.
Insights
New lipoglycopeptide dalbavancin offers effective treatment for skin and soft tissue infections (SSTIs). Its long-acting properties allow infrequent dosing, potentially enabling outpatient care and earlier hospital discharge for patients with MRSA.
Area of Science:
- Infectious Diseases
- Pharmacology
- Dermatology
Background:
- Skin and soft tissue infections (SSTIs) are a growing concern, frequently caused by Staphylococcus aureus.
- The rise of methicillin-resistant Staphylococcus aureus (MRSA) complicates treatment and increases morbidity.
Purpose of the Study:
- To review the pharmacokinetic properties of dalbavancin.
- To evaluate the clinical evidence for dalbavancin in treating complicated SSTIs.
Main Methods:
- Review of pharmacokinetic data for dalbavancin.
- Analysis of clinical studies on dalbavancin for SSTI treatment.
Main Results:
- Dalbavancin demonstrates high activity against Gram-positive bacteria, including resistant strains.
- It possesses a prolonged half-life (approx. 14 days), enabling once-weekly dosing.
- Dalbavancin shows a favorable safety profile.
Conclusions:
- Dalbavancin is a promising lipoglycopeptide for SSTI treatment.
- Its pharmacokinetic profile supports outpatient management and early hospital discharge.
- It represents a valuable new option against drug-resistant Gram-positive pathogens.
Related Concept Videos
01:23Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
01:02Role of Septins
Cellular Functions of Septins
Recent studies have revealed the multifaceted roles of septins in various cellular processes such as cytokinesis, ciliogenesis, and neurogenesis. Septins act as scaffolds and...
01:23The Role of Culture
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:21Role-Based Identity
01:19Role of Hippocampus in Memory